Jiangsu Kanion Pharmaceutical Co Ltd (600557) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jiangsu Kanion Pharmaceutical Co Ltd (600557) has a cash flow conversion efficiency ratio of 0.041x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥201.83 Million ≈ $29.53 Million USD) by net assets (CN¥4.91 Billion ≈ $718.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jiangsu Kanion Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Jiangsu Kanion Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Jiangsu Kanion Pharmaceutical Co Ltd (600557) total liabilities for a breakdown of total debt and financial obligations.
Jiangsu Kanion Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jiangsu Kanion Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SMA SOLAR T. UNSP.ADR/01
F:S93
|
N/A |
|
B.Grimm Power Public Company Limited
BK:BGRIM
|
0.092x |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
0.084x |
|
Inner Mongolia ERDOS Resources Co Ltd B
SHG:900936
|
0.083x |
|
Netcare
JSE:NTC
|
0.220x |
|
Wuxi Online Offline Communication Information Technology Co. Ltd.
SHE:300959
|
N/A |
|
SUFA Technology Industry Co Ltd CNNC
SHE:000777
|
0.002x |
|
Lindblad Expeditions Holdings Inc
NASDAQ:LIND
|
-0.152x |
Annual Cash Flow Conversion Efficiency for Jiangsu Kanion Pharmaceutical Co Ltd (2001–2024)
The table below shows the annual cash flow conversion efficiency of Jiangsu Kanion Pharmaceutical Co Ltd from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see 600557 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥4.71 Billion ≈ $688.50 Million |
CN¥702.49 Million ≈ $102.80 Million |
0.149x | -17.38% |
| 2023-12-31 | CN¥5.38 Billion ≈ $787.34 Million |
CN¥972.32 Million ≈ $142.28 Million |
0.181x | -10.47% |
| 2022-12-31 | CN¥4.93 Billion ≈ $722.00 Million |
CN¥995.94 Million ≈ $145.74 Million |
0.202x | -0.60% |
| 2021-12-31 | CN¥4.47 Billion ≈ $654.50 Million |
CN¥908.30 Million ≈ $132.91 Million |
0.203x | +25.32% |
| 2020-12-31 | CN¥4.33 Billion ≈ $633.14 Million |
CN¥701.10 Million ≈ $102.59 Million |
0.162x | -28.45% |
| 2019-12-31 | CN¥4.09 Billion ≈ $598.12 Million |
CN¥925.73 Million ≈ $135.46 Million |
0.226x | +38.52% |
| 2018-12-31 | CN¥3.89 Billion ≈ $569.56 Million |
CN¥636.39 Million ≈ $93.12 Million |
0.164x | +53.44% |
| 2017-12-31 | CN¥3.59 Billion ≈ $525.84 Million |
CN¥382.93 Million ≈ $56.03 Million |
0.107x | +14.25% |
| 2016-12-31 | CN¥3.21 Billion ≈ $469.11 Million |
CN¥299.02 Million ≈ $43.76 Million |
0.093x | -47.99% |
| 2015-12-31 | CN¥2.87 Billion ≈ $420.08 Million |
CN¥514.80 Million ≈ $75.33 Million |
0.179x | +47.14% |
| 2014-12-31 | CN¥2.56 Billion ≈ $374.06 Million |
CN¥311.54 Million ≈ $45.59 Million |
0.122x | -39.25% |
| 2013-12-31 | CN¥1.93 Billion ≈ $283.08 Million |
CN¥388.11 Million ≈ $56.79 Million |
0.201x | +56.12% |
| 2012-12-31 | CN¥1.65 Billion ≈ $241.54 Million |
CN¥212.11 Million ≈ $31.04 Million |
0.129x | +110.14% |
| 2011-12-31 | CN¥1.47 Billion ≈ $215.81 Million |
CN¥90.19 Million ≈ $13.20 Million |
0.061x | -54.27% |
| 2010-12-31 | CN¥1.24 Billion ≈ $182.08 Million |
CN¥166.40 Million ≈ $24.35 Million |
0.134x | +759.34% |
| 2009-12-31 | CN¥1.08 Billion ≈ $157.77 Million |
CN¥-21.87 Million ≈ $-3.20 Million |
-0.020x | -133.16% |
| 2008-12-31 | CN¥954.72 Million ≈ $139.71 Million |
CN¥58.39 Million ≈ $8.54 Million |
0.061x | -63.20% |
| 2007-12-31 | CN¥557.95 Million ≈ $81.65 Million |
CN¥92.73 Million ≈ $13.57 Million |
0.166x | -24.83% |
| 2006-12-31 | CN¥492.91 Million ≈ $72.13 Million |
CN¥108.98 Million ≈ $15.95 Million |
0.221x | -0.20% |
| 2005-12-31 | CN¥457.89 Million ≈ $67.00 Million |
CN¥101.44 Million ≈ $14.84 Million |
0.222x | +323.09% |
| 2004-12-31 | CN¥414.10 Million ≈ $60.60 Million |
CN¥21.68 Million ≈ $3.17 Million |
0.052x | +14.61% |
| 2003-12-31 | CN¥374.88 Million ≈ $54.86 Million |
CN¥17.13 Million ≈ $2.51 Million |
0.046x | +36.56% |
| 2002-12-31 | CN¥333.38 Million ≈ $48.78 Million |
CN¥11.15 Million ≈ $1.63 Million |
0.033x | -88.24% |
| 2001-12-31 | CN¥73.91 Million ≈ $10.82 Million |
CN¥21.02 Million ≈ $3.08 Million |
0.284x | -- |
About Jiangsu Kanion Pharmaceutical Co Ltd
Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. It also offers medicines in the fields of anti-infections, orthopedics, gynecology, cardio and cerebrovascular, tonic-class, and others. In addition, the company provides herb extracts and formula granules, as well as OEM/ODM services. Jiangsu Kanion Pharmaceutical Co.,Ltd. was founded in 1975 a… Read more